10443 results for 'nike anti'

What You Need to Know About OzuriftamabWhat is Ozuriftamab?Ozuriftamab is an investigational monoclonal antibody targeting CD47, designed to enhance immune-mediated clearance of cancer c

Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha

Key Facts About EtigilimabWhat is Etigilimab?Etigilimab is an anti-TIGIT monoclonal antibody being studied for its potential role in cancer immunotherapy.What role does Etigilimab play i

Quick Info Section: Key Facts About CevostamabWhat is Cevostamab?Cevostamab is an investigational monoclonal antibody targeting CD47, a cell surface protein that helps cancer cells evade

Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen

Quick Facts About NarnatumabWhat is Narnatumab?Narnatumab is a monoclonal antibody targeting CD47, a key immune checkpoint that helps cancer cells evade destruction by the immune system.

What You Need to Know About MagrolimabWhat is Magrolimab?Magrolimab is an anti-CD47 monoclonal antibody that targets the "don't eat me" signal on cancer cells, promoting their destructio

Quick Facts About TesnatilimabWhat is Tesnatilimab?Tesnatilimab is an anti-CD47 monoclonal antibody designed to block the "don’t eat me" signal used by cancer cells to evade immune respo

Quick Facts About LirilumabWhat is Lirilumab?Lirilumab is an anti-KIR monoclonal antibody designed to enhance natural killer (NK) cell activity by blocking killer-cell immunoglobulin-lik

Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest

Key Facts About BrentuximabWhat is Brentuximab?Brentuximab is a monoclonal antibody targeting CD30, commonly used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell

Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance

Quick Facts About LacnotuzumabWhat is Lacnotuzumab?Lacnotuzumab is a monoclonal antibody targeting CD47, a protein that helps cancer cells evade immune system destruction.What is the mec

What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c

In recent years, cancer immunotherapy has become a powerful tool for treating various malignancies. One promising approach involves targeting the tumor microenvironment, particularly regu

Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat

Quick Facts About RuplizumabWhat is Ruplizumab?Ruplizumab is an investigational monoclonal antibody designed to target CD47, a protein that helps cancer cells evade immune detection.What

What You Need to Know About BersanlimabWhat is Bersanlimab?Bersanlimab is a cutting-edge anti-CD47 monoclonal antibody designed to disrupt cancer cells' evasion of immune detection.What

What You Need to Know About PrezalumabWhat is Prezalumab?Prezalumab is a monoclonal antibody designed to target CD47, a protein often overexpressed in cancer cells to evade immune detect

Quick Facts About IcrucumabWhat is Icrucumab?Icrucumab is a monoclonal antibody that targets vascular endothelial growth factor receptor-1 (VEGFR-1) to inhibit tumor angiogenesis.How Doe

Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli

Quick Facts About NadecnemabWhat is Nadecnemab?Nadecnemab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint protein involved in cancer evasion.How Does

What You Need to Know About IfabotuzumabWhat is Ifabotuzumab?Ifabotuzumab is a monoclonal antibody targeting EphA3, a receptor tyrosine kinase overexpressed in certain cancers. It plays

Quick Facts About AtezolizumabWhat is Atezolizumab?Atezolizumab is an anti-PD-L1 monoclonal antibody used in immunotherapy to treat various cancers by enhancing the immune system's abili

Quick Facts About UliledlimabWhat is Uliledlimab?Uliledlimab is a monoclonal antibody targeting CD47, a checkpoint protein that helps tumors evade immune system detection. By blocking CD

Key Facts About EnoblituzumabWhat is Enoblituzumab?Enoblituzumab is a monoclonal antibody targeting the B7-H3 protein, which is expressed on the surface of various cancer cells, includin

Quick Facts About RosopatamabWhat is Rosopatamab?Rosopatamab is a monoclonal antibody targeting CD47, a critical immune checkpoint that helps cancer cells evade immune detection. By bloc

Quick Facts About IndusatumabWhat is Indusatumab?Indusatumab is an experimental antibody therapy targeting CD47, a protein that enables cancer cells to evade immune destruction.How does

Quick Facts About PlonmarlimabWhat is Plonmarlimab?Plonmarlimab is a monoclonal antibody targeting GM-CSF, a cytokine involved in inflammation and immune responses.How does Plonmarlimab

Introduction to SLAMF7 in Cancer Immunotherapy SLAMF7, also known as Signaling Lymphocytic Activation Molecule F7, is a surface receptor found on natural killer (NK) cells, T cells, plasm

Quick Facts About LitifilimabWhat is Litifilimab?Litifilimab is a monoclonal antibody developed by Biogen targeting BDCA2, a receptor on plasmacytoid dendritic cells (pDCs), to regulate

Quick Facts About PamrevlumabWhat is Pamrevlumab?Pamrevlumab (FG-3019) is a monoclonal antibody designed to target and inhibit the connective tissue growth factor (CTGF), a key driver of

Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther

What You Need to Know About BermekimabWhat is Bermekimab?Bermekimab is a monoclonal antibody targeting the CD47 receptor, developed to modulate the immune system and improve conditions l

Quick Facts About EldelumabWhat is Eldelumab?Eldelumab is a monoclonal antibody targeting TNFSF14 (LIGHT), a key regulator in immune system signaling, with potential applications in infl

Quick Info Section: Key Facts About PlozalizumabWhat is Plozalizumab?Plozalizumab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint in cancer cells. By

Secondary Antibodies | HRP, FITC, Cy3 & AP Conjugates | Assay Genie

Research Antibodies: Primary, Secondary & In Vivo | Assay Genie

Loading Control Antibodies | GAPDH, \u03b2-Actin & Tubulin | Assay Genie

Therapeutic Antibody & Biosimilar ELISA Kits | Free Drug & ADA | Assay Genie

KO Validated Antibodies | Assay Genie

Flow Cytometry Antibodies | 16,900+ Conjugates & Panel Builder | Assay Genie

1. What is a Biosimilar? A biosimilar is a biologic medical product that is highly similar to an already-approved reference biologic. While minor differences in clinically inactive compon

Quick Facts About GlenzocimabWhat is Glenzocimab?Glenzocimab is an innovative monoclonal antibody designed to reduce the risk of ischemic stroke by selectively targeting platelet glycopr

Quick Facts About FarletuzumabWhat is Farletuzumab?Farletuzumab is a humanized monoclonal antibody targeting folate receptor alpha (FRα), a protein overexpressed in ovarian and other epi

ChIP Antibodies | ChIP-Validated Histone & TF Antibodies | Assay Genie

Epigenetic Antibodies | 81+ Histone Acetylation & Methylation Antibodies | Assay Genie

IHC Antibodies | Validated Antibodies for Accurate IHC Staining | Assay Genie

Custom Antibody Production Service | Assay Genie

Antibody Sampler Packs | Assay Genie

Custom In Vivo Antibody Service | Assay Genie

In Vivo Antibody Sampler Packs | Checkpoint & Depletion Panels | Assay Genie

Targeting USP22: A New Approach to Enhance Anticancer Immunity Introduction In the ever-evolving landscape of cancer research, the intricate relationship between immune e

Exploring the Role of TIM-3/Gal-9 in Antiparasitic ImmunityIntroductionThe immune system is a complex network of cells and molecules that work together to defend the body against pathogens, including

Sweet Deception: How a New Antibody Therapy Unmasks Pancreatic Cancer Sweet Deception: How a New Antibody Therapy Unmasks Pancreatic Cancer Pancreatic canc

Treponema pallidum, the causative agent of syphilis, triggers an immune response that produces antibodies detectable by laboratory tests. Diagnosing syphilis often involves detecting thes

CB6, also known as Etesevimab, is a monoclonal antibody that targets the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. It neutralizes the virus by preventing it from bind

Immune evasion is one of the hallmarks of cancer, where tumor cells employ various strategies to suppress immune responses and prevent destruction by the body’s defense systems. CD200, a

Recent advances in immunotherapy have highlighted the importance of targeting immune checkpoints to enhance the immune system’s ability to combat cancer. A new potential target in this gr

One of the greatest challenges in cancer therapy is how tumors evade immune detection. Among the mechanisms cancer cells exploit, the CD47 pathway has emerged as a major player in helping

Immunotherapy has transformed the landscape of cancer treatment by leveraging the body’s immune system to target and destroy cancer cells. A key player in this process is Inducible T-cell

The recent advances in cancer immunotherapy have brought new opportunities to harness the body’s immune system against tumors. Among these advancements is the targeting of immune checkpoi

Cancer cells are adept at avoiding destruction by the immune system, often exploiting specific pathways to escape detection and elimination. One of these key mechanisms involves the SIRPα